Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Atezolizumab added to chemotherapy prolongs progression free survival in...

Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain

Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

Comment: Keynote 522 trial

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy

Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )

Immunotherapy added to chemotherapy improves pathological complete response in...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous...

Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma ( Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea )

Ovarian highlights from ESMO 2019

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian...

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

Dr Marina Garassino - National Tumor Institute, Milan, Italy

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer...

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )

Nivolumab plus ipilimumab combination offers chemotherapy-free option for...

Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )

More from ecancer